Vive la Différence: The Beauty of Diversity in Life, Life Science, and Flow Cytometry
The differences between us are what makes life interesting, and diversity in a group that shares a common goal can lead to many benefits. Here we examine the similarities and differences between researchers using flow cytometry for academic research and those using it for drug discovery. We outline the challenges they face and learn that they share a common goal as well as a common solution.
Biotherapeutic Antibody Discovery at Bio-Rad’s New Center for Excellence
The Pioneer Platform features one of the largest functional antibody libraries available, utilizing SpyLock technology for rapid prototyping and screening of hundreds of bispecific antibodies, and TrailBlazer technology for efficient antibody format conversion. Together, these services provide a comprehensive and streamlined solution for researchers seeking to develop innovative biotherapeutic therapies.
Cytometry in Drug Discovery: An Introduction to Regulation, Standardization, and Productivity
Many researchers learn flow cytometry in academia, but find new challenges in the commercial sector. In this webinar, learn about regulatory issues and more.
10 Key Factors for Achieving Accurate Cell Counts: Tips, Tricks, and Myths
Counting is something we are all familiar with but it’s not always as simple as one, two, three. Measuring the concentration of cells in suspension is a common but surprisingly complex task in cell biology that is easy to get wrong. This article explores ten factors that can influence cell counting, gives advice on how to improve accuracy, and dispels some commonly held myths.
Faster PCR and Flow Cytometry Highlighted in Annual Lab Automation Roundup
The annual international Society for Laboratory Automation and Screening (SLAS) conference is the highlight of the year for scientists in academia, industry, and government focused on leveraging the power of automation to achieve scientific breakthroughs. Here are some highlights of this year’s conference and how Bio-Rad contributed to it.
Flow Cytometry and the Law of Bottlenecks
Manufacturing and high-throughput screening may seem to have very little in common, but they are related at a fundamental level. Both seek to transform a raw material into a finished product, and both struggle with constraints, or bottlenecks, that reduce efficiency. How can we apply the revolutionary 20th century management principles of continuous improvement to 21st century flow cytometry?
Rising from the Ashes: The History of the 488 nm Laser
Despite the pivotal role of the 488 nm (blue) laser in the rise in popularity of flow cytometry, it experienced somewhat of a fall from grace following the shift to higher usage of the 561 nm (yellow) laser. However, with the advancement of flow cytometry leading to the use of more complex multicolor panels and ever-increasing fluorophore numbers per experiment, the blue laser is starting to make a comeback. Discover how StarBright Blue Dyes can help you make the most out of your 488 nm laser.
StarBright Dyes for Flow Cytometry
Watch this video to learn about the many benefits of StarBright Dyes — our proprietary fluorescent nanoparticles — and see how they can help you build bigger, better flow cytometry panels with ease. StarBright Dyes have been designed to be stable, with superior brightness, narrow excitation and emission characteristics, and the flexibility to be included in new and existing experiments. They offer improved resolution of specific cell populations and minimized spillover and spreading.
Developing Biotherapeutics for Lung Cancer Treatment
In recent years, biologics — drugs derived from living culture systems — have become increasingly significant in the fight against a plethora of conditions. Unfortunately, the efficiency of these drugs comes at a cost. A daily dose of a biologic drug costs, on average, 22 times more than conventional small-molecule drugs. Therefore, biosimilars are developed to make them more accessible. Lung cancer is an example where the development of biosimilars could increase treatment options available for patients.
The Pioneer Antibody Discovery Platform: Clinical-Quality Lead Candidates in Industry-Leading Timelines
Biotherapeutic antibody discovery is inherently challenging. Amongst the clinically proven technologies for antibody discovery is phage display — a technique utilized by one of the most recent and innovative solutions on the market: the Pioneer Antibody Discovery Platform.